The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://tamzinespc379821.wikigop.com/1858987/retatrutide_vs_tirzepatide_a_comparative_analysis